Related Experiment Video
Updated: Jun 22, 2025
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A
Azza Sarfraz1, Zouina Sarfraz2, Shehar Bano2
1Aga Khan University, Karachi, Pakistan.
Insights
This review examines cardiovascular outcomes of repurposed therapies used during the COVID-19 pandemic. It clarifies the rationale for clinical trials and future directions for pandemic drug repurposing.
Area of Science:
- Cardiology
- Pharmacology
- Infectious Diseases
Background:
- The COVID-19 pandemic accelerated the repurposing of existing therapies for novel applications.
- Many repurposed drugs, previously used for influenza and Ebola, were investigated during the pandemic.
- Understanding the cardiovascular implications of these therapies is crucial.
Purpose of the Study:
- To establish a comprehensive understanding of the cardiovascular outcomes associated with repurposed therapies during the COVID-19 pandemic.
- To elucidate the rationale behind clinical trials involving repurposed drugs in a pandemic context.
- To guide future therapeutic strategies and clinical trial designs for pandemic preparedness.
Main Methods:
- State-of-the-art literature review.
- Analysis of cardiovascular involvement of repurposed therapies.
- Examination of clinical trial data and outcomes.
Main Results:
- The review synthesizes current knowledge on the cardiovascular effects of repurposed drugs.
- Identifies patterns in cardiovascular complications and benefits across different therapeutic agents.
- Highlights the importance of cardiovascular monitoring in repurposed therapy trials.
Conclusions:
- Repurposed therapies during pandemics necessitate thorough cardiovascular risk-benefit assessments.
- A deeper understanding of cardiovascular involvement informs safer and more effective clinical trial designs.
- This review provides a foundation for optimizing drug repurposing strategies in future public health emergencies.
Abstract:
The COVID-19 pandemic has resulted in many therapies, of which many are repurposed and used for other diseases in the last decade such in Influenza and Ebola. We intend to provide a robust foundation for cardiovascular outcomes of the therapies to better understand the rationale for the clinical trials that were conducted during the COVID-19 pandemic, and to gain more clarity on the steps moving forward should the repurposing provide clinical benefit in pandemic situations. With this state-of-the-art review, we aim to improve the understanding of the cardiovascular involvement of the therapies prior to, during, and after the COVID-19 pandemic to provide meaningful findings to the cardiovascular specialists and clinical trials for therapies, moving on from the period of pandemic urgency.
More Related Videos
Related Concept Videos
01:26Longitudinal Studies
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:11Clinical Trials: Overview
01:21Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...